✦ LIBER ✦

Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach

✍ Scribed by Ilya A. Lipkovich; Walter Deberdt; John G. Csernansky; Peter Buckley; Joseph Peuskens; Sara Kollack-Walker; Matthew Rotelli; John P. Houston

Book ID: 116849676
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 351 KB
Volume: 170
Category: Article
ISSN: 0165-1781
DOI: 10.1016/j.psychres.2008.09.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcomes and Costs of Risperidone versus

Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model

✍ Montserrat Vera-Llonch; Thomas E Delea; Erin Richardson; Marcia Rupnow; Amy Grog 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

Comments to the Editor on “Outcomes and

Comments to the Editor on “Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model”

📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Incidence and costs of polypharmacy: dat

Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder*

✍ Rupnow, Marcia F. T.; Greenspan, Andrew; Gharabawi, Georges M.; Kosik-Gonzalez, 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 387 KB